Doses - SELEGILINE HCL, L-DEPRENYL

Dogs:

For Cushing's Disease:
a) 1 mg/kg PO in the AM (with food prn); Reevaluate clinically over next 2 mos.; if noimprovement, may increase to 2 mg/kg once daily; if no improvement or signs increase, reevaluate diagnosis or consider alternate treatment (Package Insert; Anipryl®;¯Pfizer)
For Canine Cognitive Dysfunction:
a) 0.5 mg/kg PO in the AM (with food prn); Reevaluate clinically over next 2 mos.; if noimprovement, may increase to 1 mg/kg once daily (Canadian product label directions)
Monitoring Parameters - Clinical efficacy and adverse effects. No correlation between low dosedexamethasone suppression test results and clinical efficacy of the drug. The manufacturerrecommends physical exam and history as the primary methods to measure response to therapy.
Client Information - Keep this and all medications out of reach of children. Have clients monitorclosely for adverse effects. Clients should be advised on the importance of complying with thedosing recommendations so as to adequately evaluate therapeutic response to the drug.
Dosage Forms/Preparations/FDA Approval Status - Veterinary-Approved Products:
Selegiline HCl Oral Tablets 2 mg, 5 mg, 10 mg, 15 mg, 30 mg in blister-packs of 30 tablets;
Anipryl® (Pfizer); (Rx). Approved for use in dogs.

Human-Approved Products:

Selegiline HCl Oral Tablets and Capsules 5 mg; Eldepryl®; Capsules (Somerset); Atapryl®;
Tablets (Athena); Generic Tablets; (Rx)